Index pharmaceuticals announces license agreement with viatris japan to develop and commercialize cobitolimod in japan

Stockholm , may 31, 2023 /prnewswire/ -- index pharmaceuticals holding ab (publ) ("index") today announced that a license agreement has been signed with viatris pharmaceutical japan inc. ("viatris japan") to register and commercialize cobitolimod in japan for the treatment of ulcerative colitis. cobitolimod is a tlr9 agonist which is being evaluated in the global phase iii program conclude, as a novel treatment for moderate to severe ulcerative colitis.
VTRS Ratings Summary
VTRS Quant Ranking